Abstract:Objective To investigate the protective effect of Astragalus injection combined with mild hypothermia on the brain of patients with acute cerebral infarction after thrombolysis. Methods A total 74 patients with acute cerebral infarction who were treated with ateplase thrombolysis from March 2015 to November 2018 were randomly divided into control group and observation group (n=37, each). The control group was treated with hypothermia after thrombolysis for 72 hours; the observation group was treated with Astragalus injection 20 ml intravenous drip combined with mild hypothermia after thrombolysis for two weeks. The clinical efficacy, the levels of superoxide dismutase (SOD), malondialdehyde (MDA), interleukin (IL)-1β, tumor necrosis factor (TNF)-α and the adverse reactions were compared between the two groups. Results The effective rate of the control group was significantly lower than that of the observation group (78.38% vs 94.59%,χ²=4.163, P=0.041). There was no significant difference in SOD, MDA, IL-1β, TNF-α between the two groups at different time points (all P>0.05). There were significant differences of SOD, MDA, IL-1β, TNF-α between the control group and the observation group at 1 day and 2 weeks after thrombolysis (all P<0.01). There was no significant difference between the control group and the observation group (13.51% vs 18.92%, P>0.05). Conclusion Astragalus injection combined with mild hypothermia can improve ischemia-reperfusion in patients with acute cerebral infarction after thrombolysis, which is related to antioxidant stress and reduce inflammatory factors, and the patients can tolerate it.